<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546936</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4145s</org_study_id>
    <nct_id>NCT00546936</nct_id>
  </id_info>
  <brief_title>Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis</brief_title>
  <official_title>Ranibizumab vs PDT for Presumed Ocular Histoplasmosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barnes Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barnes Retina Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the change in visual activity of ranibizumab to
      Photodynamic Therapy (PDT)in patients with choroidal neovascularization (CNV) secondary to
      presumed ocular histoplasmosis
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in visual acuity</measure>
    <time_frame>6 months, 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate mean change in vision at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Presumed Ocular Histoplasmosis (POHS)</condition>
  <arm_group>
    <arm_group_label>ranibizumab intravitreal injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg intravitreal injection of ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photodynamic therapy with Visudyne</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>0.5mg ranibizumab</description>
    <arm_group_label>ranibizumab intravitreal injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verteporfin</intervention_name>
    <description>Photodynamic therapy with verteporfin every 3 months for 1 year</description>
    <arm_group_label>Photodynamic Therapy</arm_group_label>
    <other_name>Visudyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subfoveal CNV due to presumed ocular histoplasmosis of less than 1 year duration

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age greater than or equal to 21 years of age

          -  CNV lesion of than &lt; 5400 microns in diameter

          -  Best corrected visual acuity of 20/40-20/320

          -  Birth control therapy for females of child-bearing potential

        Exclusion Criteria:

          -  Subfoveal NCV due tp presumed ocular histoplasmosis for &gt; 1 year

          -  Pregnancy or lactation premenopausal women not using adequate contraception

          -  Prior enrollment in the study

          -  Any other condition that the Investigator believes would pose a significant hazard to
             the subject

          -  Participation in another simultaneous medical investigation or trial

          -  Participation in another trial or previous trial of ranibizumab or Avastin

          -  Any concurrent ocular condition in the study eye (cataract, diabetic retinopathy)that
             could require medical or surgical intervention or ifa allowed to progress, could
             likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the
             12-month study period

          -  Previous panretinal photocoagulation

          -  Previous steroids or PDT in 3 months

          -  Previous participation in any studies of investigational drugs within 30 days
             preceding Day 0

          -  Prior participation in a Genentech ranibizumab clinical trial

          -  Previous treatment with intravitreally (in either eye) or intravenously administered
             Avastin within 3 months

          -  Previous use of Macugen in the study eye within 3 months

          -  Prior submacular surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin J. Blinder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barnes Retina Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ginny S Nobel, COT</last_name>
    <phone>314-367-1278</phone>
    <phone_ext>2305</phone_ext>
    <email>bristudy@barnesretinainstitute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Walters, COT</last_name>
    <phone>314-367-1278</phone>
    <phone_ext>2312</phone_ext>
    <email>bristudy@barnesretinainstitute.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Macula-Retina-Vitreous Service, Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46280</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neelam Thukral</last_name>
      <phone>317-805-2152</phone>
      <email>neelamt@midwest.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Ciulla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Retina Institute</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginny S Nobel, COT</last_name>
      <phone>314-367-1278</phone>
      <phone_ext>2305</phone_ext>
      <email>bristudy@barnesretinainstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Carol L Walters, COT</last_name>
      <phone>314-367-2287</phone>
      <phone_ext>2312</phone_ext>
      <email>bristudy@barnesretinainstitute.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin J Blinder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>April 15, 2009</last_update_submitted>
  <last_update_submitted_qc>April 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kevin Blinder, MD</name_title>
    <organization>Barnes Retina Institute</organization>
  </responsible_party>
  <keyword>Histoplasmosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histoplasmosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

